Summit Therapeutics Inc. (NASDAQ:SMMT) is gaining attention in the pharmaceutical industry. Citigroup recently initiated coverage on SMMT, assigning it a "Buy" rating with the stock priced at $18.81. This move highlights the company's potential in the competitive drug market, as noted in Benzinga's article "Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst."
Stifel also initiated coverage on Summit, focusing on its promising lead drug candidate, ivonescimab. This PD-1xVEGF bispecific antibody targets lung cancer, a significant area of need. Stifel's "Buy" rating and a price target of $45 reflect confidence in Summit's innovative approach and market potential.
Ivonescimab is undergoing extensive testing, with 14 Phase 3 studies. Ten of these are conducted in China by Akeso, while four are Summit-sponsored global studies. This extensive research underscores the drug's potential impact on lung cancer treatment, particularly for patients with specific genetic mutations.
In January, the FDA accepted Summit's Biologics License Application for ivonescimab. This application is for its use in combination with chemotherapy for certain lung cancer patients. The FDA's PDUFA goal action date is set for November 14, marking a crucial milestone for the company.
Summit's strategic focus on ivonescimab positions it well in the pharmaceutical landscape. With strong backing from major analysts and ongoing clinical trials, the company is poised to make significant strides in cancer treatment.
